FB825
Phase 2Small molecule
FB825 is one of 66 small molecule programs targeting Allergic Asthma. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Ciclosporin
NovartisPhase 3
GR1802
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
Elidel
BayerPhase 3
Verdeso
PPadagis LLC
Phase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ketotifen Fumarate
Tanabe Pharma CorporationPhase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis3 trials
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FB825. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OOneness Biotech Co., Ltd.